Prime Msk Shot is under clinical development by Thomas Advanced Medical and currently in Phase II for Unspecified Neurologic Disorders. According to GlobalData, Phase II drugs for Unspecified Neurologic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Prime Msk Shot LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prime Msk Shot overview
PRIME msk shot is under development for treatment of autoimmune diseases, cardiovascular disorders, diabetes complications, integumentary disease, musculoskeletal disorders, neurodegenerative disorders, pulmonary disorders, sexual dysfunction, urologic disorders and viral illnesses. It comprises of allogeneic, minimally manipulated human umbilical cord tissue derived stem cells with Wharton’s jelly. It is administered through intraarticular, subcutaneous and intramuscular routes.
Thomas Advanced Medical overview
Thomas Advanced Medical is developing regenerative medicine for the treatment of lung disease and neurodegenerative diseases. The company is headquartered in Carson, California, the US.
For a complete picture of Prime Msk Shot’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
